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ABSTRACT  
Objective: The Brazilian National Health System provides high cost medicines through the 
Specialized Component of Pharmaceutical Assistance in accordance with adherence to agreed 
Clinical Guidelines. However, physician compliance to these Guidelines, as well as the barriers 
and facilitators related to them and the influence on the subsequent quality of care provided is 
unknown. Consequently, the objectives of this paper are to undertake a review of international 
experiences and scientific publications of a strategy to disseminate and communicate guidelines 
to physicians through Academic Detailing. Subsequently use the findings to develop and 
conduct a pilot Academic Detailing Program in Brazil targeting specialists who prescribe 
PHGLFLQHVIRUSDWLHQWVZLWK$O]KHLPHU¶VGLVHDVHZKLFKDUHSDUWRIWKH6SHFLDOL]HG&RPSRQHQW
of Pharmaceutical Assistance. Methods: Review international experiences and scientific 
publications relating to academic detailing based on a thorough review of available literature 
including publications known to the co-authors. Develop and monitor physician acceptance of 
academic detailing IRUSDWLHQWVZLWK$O]KHLPHU¶V'LVHDVHand the impact on future prescribing. 
Key findings: Based on the lessons learnt from the international experience and review, coupled 
with the initial experiences in Brazil, we conclude that conducting academic detailing  to 
enhance the implementation and dissemination of clinical protocols and therapeutic guidelines 
in Brazil is worthwhile. We will be closely monitoring the outcome of the pilot academic detailing 
programme as a basis for developing future programmes to further improve the quality of 
prescribing in Brazil. Conclusion: Findings from the experiences are encouraging. This will be 
further explored to provide a basis for this approach in the future. 
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INTRODUCTION 
x The Brazilian Healthcare System, Clinical Protocols and Therapeutic Guidelines 
(CPTG)  
3KDUPDFHXWLFDODVVLVWDQFHLQ%UD]LOLVFRQVLGHUHGDULJKWRIWKHFLWL]HQDQGLW¶VSURYLGHGE\WKH
Brazilian National Health System (SUS)(1) according to the three groups of medicines in which 
pharmaceutical assistance is organized.  
The Specialized Component of Pharmaceutical Assistance (CEAF) includes "high cost" 
medicines for the treatment of specific diseases that affect a limited number of patients (2). 
Access to medicines in CEAF depends on compliance with the Clinical Protocols and 
Therapeutic Guidelines (CPTGs) published by the Ministry of Health; otherwise 100% patient 
co-payment for the medicines (2,3). Requests for access is checked by each State Department 
of Health or those contracted to them such as the SUS Collaborating Centre ± Health 
Technology Assessment & Excellence at the College of Pharmacy, Federal University of Minas 
Gerais. Refusals due to a lack of compliance with the guidelines mean a long wait for both 
physicians and patients until the correct forms are returned, checked and approved, which is not 
in the best interest of any key group.  
However, translating scientific evidence of CPTGs into daily practice is complex. Clinical 
guidelines can improve health care delivery, but there are a number of challenges in guideline 
adoption and implementation (4-6). These challenges are heightened if there is mistrust in the 
guidelines produced. This can be addressed by rigorous approaches, including robust conflict of 
interest regulations (7, 8). In addition, physicians can have guideline overload. This was seen in 
France with the RMO (références médicales opposables) guidelines for ambulatory care 
physicians where 243 had been developed by the authorities by the time this initiative was 
abandoned (9). A more measured approach was seen in Austria where only one guideline is 
produced per year involving all key stakeholder groups, with good acceptance and impact (10). 
Another challenge for CPTG implementation are potential counter-balancing activities by 
pharmaceutical companies, with companies spending up to one third of their income on 
promotional and other marketing expenses. In 2012, this represented $24 billion in marketing 
costs to health care professionals in the US (11-13). A recent meta-analysis of studies of 
physicians exposed to information from pharmaceutical companies found this exposure was 
associated with a higher prescribing frequency, higher costs, and/or lower prescribing quality 
with no improvement in prescribing (13). Such concerns have resulted in countries introducing 
measures to limit pharmaceutical company marketing activities. These include fines and other 
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measures for abuse (14-16). Alongside this, measures to enhance the rational use of 
medicines, including Academic Detailing.  
Academic detailing has been described as a relatively strong strategy to disseminate guidelines 
(17), addressing concerns with current prescribing practices including the inappropriate use of 
medicines. Its method combines the interactive marketing approach used by pharmaceutical 
company sales forces with evidence-based, unbiased information, from academic sources. As a 
result, academic detailing aims to close the gap between the best available evidence and 
prescribing in routine clinical practice to improve clinical decision making and enhance the 
quality and cost-effectiveness of care.a,(18) 
Accordingly, this study aimed to evaluate the scientific evidence coupled with international 
experiences to support a proposal for academic detailing in Brazil, targeting guidelines-based 
dissemination under the Specialized Component of Pharmaceutical Assistance. The first 
JXLGHOLQHVDUHWKRVHIRU$O]KHLPHUV¶'LVHDVH 
x Concepts and terminology surrounding academic detailing 
Academic detailing, or educational outreach visits, corresponds to the visit of a trained person 
(health professional or not) to health professionals in their own settings (hospital, nursing home, 
office) (19) conducted on a one-on-one basis.  
Visits are traditionally delivered to general practitioners; however, they can be directed to 
specialists, nurses, or pharmacists. The aim is to provide information with the intent of changing 
KHDOWKSURIHVVLRQDOV¶EHKDYLRU7KHYLVLWVFDQKDYHDUDQJHRIJRDOV. These include: 
development and dissemination of CPTGs; changing prescribing patterns including utilisation; 
changing resource patterns, e.g. increased screening for cancer or increased use of lower cost 
generics; and improving the management of targeted health conditions (19, 20). 
To achieve its objectives, academic detailing is commonly delivered in one or more visits and is 
often combined with other strategies, as part of a multi-faceted intervention (19). These other 
strategies can include for instance mailed information, reminders, audits and feedback (Table 
1).   
  
                                                             
aNational Resource Center for Academic Detailing  (NaRCAD). About Academic Detailing. [cited 
2015 Jan 22]. Available from: http://www.narcad.org/about/aboutad/ 
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Table 1: Types of intervention  
Intervention Description 
Audit and feedback 
Any summary of clinical performance of health care over a specified 
period of time, with or without recommendations for clinical action  
Conferences and training 
Participation of health care providers in conferences, lectures, 
workshops or traineeships outside their practice settings 
Educational materials 
Published or printed recommendations for clinical care, including 
clinical practice guidelines, audiovisual materials and electronic 
publications, delivered personally or through mass mailings 
Educational outreach visits 
Use of a trained person who meets with providers in their practice 
settings to provide information with the intent of changing the 
SURYLGHU¶VSUDFWLFH  
Includes Academic Detailing 
Local opinion leader 
Use of providers explicitly nominated by their colleagues to be 
educationally influential 
Other 
Other professional intervention categories of the EPOC editorial team, 
such as patient mediated interventions, local consensus processes, 
mass medias 
Adapted from the Cochrane Effective Practice and Organization of Care Group (Available from: 
http://epoc.cochrane.org/epoc-taxonomy) 
 
In general, the process to develop an academic detailing program follows the recommendation 
of Soumerai and Avorn (1990) (18). It includes: (i) identifying the gap/topic to be addressed. 
This can be done by conducting interviews to investigate baseline knowledge and motivations 
for current prescribing patterns. Alternatively via telephone enquiries with physicians, expert 
advisory groups with key informants, literature reviews, or analysis of drug utilisation data; (ii) 
planning the activities. This includes selecting which groups of clinicians or other healthcare 
professionals should be visited, e.g. family practitioners, internists, nurse practitioners, or 
physician assistants. This typically involves local opinion leaders when developing programs; 
(iii) developing key messages and printed materials. This includes defining educational and 
behavioral objectives, establishing credibility through a respected organizational identity, 
referencing authoritative and unbiased sources of information, and using concise graphic 
educational materials; (iv) hiring the detailers and training them. Typically academic detailers 
are pharmacists (or other clinicians) who are comfortable with evidence-based-medicine and 
are trained in the principles of social marketing; (v) visiting the health care provider. This 
consists of stimulating active physician participation in educational interactions, highlighting and 
repeating the essential messages, and providing positive reinforcement of improved practices in 
follow-up visits; and (vi) evaluating the results of the visit. Physicians and the academic detailers 
evaluate the visit and its content.  
x Scientific evidence of strategies for clinical guideline dissemination  
As mentioned, the dissemination and implementation of CPTGs is a complex undertaking, and 
involves not just professionals and patients, but a range of people who need to be influenced 
such as legislative and administrative personnel, with each one of them requiring different 
information and activity (21). The target audience for the dissemination of the evidence will 
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depend on the problem at hand. Considering SUS, the provision of medicines depends on 
CPTG compliance by law. Consequently, the dissemination of the evidence is mainly directed to 
prescribers and patients affected by the law. However, the approaches developed should 
consider social, political, and economic environments (22). 
The rationale for academic detailing is that the availability of CPTGs in isolation is typically not 
enough to promote a voluntary change in physician practice patterns (22), and that multiple 
approaches are needed to influence future physician prescribing. Interactive techniques have 
proven to be effective in changing physician care and patient outcomes, whilst just 
disseminating CPTGs alone has been among the least effective interventions, despite being the 
most common practice identified in 26 systematic reviews (22). Other authors have also 
documented that multiple policies, including dissemination and follow-up of guidelines, are 
needed to change prescribing behavior (5, 23-25). 
Consequently, there was a perceived need to instigate academic detailing in Brazil alongside 
dissemination of CPTGs. The objective being to enhance physician adherence to the guidelines 
to improve future care as well as potentially reduce patient co-payments, especially if 
prescriptions are denied due to physician non-adherence to the guidelines. We found only one 
study conducted in Brazil, showing that academic detailing in a hospital setting is a good 
strategy. Our challenge is to show that this strategy also works in ambulatory care. 
In view of this, the objectives of this paper are to undertake a review of international 
experiences and scientific publications of a strategy to disseminate and communicate guidelines 
to physicians via academic detailing. Secondly, use the findings to develop a pilot Academic 
Detailing Program in Brazil targeting specialists who prescribe medicines of the Specialized 
Component of Pharmaceutical Assistance for patients with $O]KHLPHU¶VGLVHDVH 
Alzheimer's disease was chosen for this pilot as it is the leading cause of irreversible dementia, 
accounting for approximately 60% of cases(26), and affects 2.03/million inhabitants in Latin 
America (27)$O]KHLPHU¶VGLVHDVHwas responsible for 1.23% (1.08-1.38).disability adjusted life 
years in Brazil in 2013b, with an annual increase of 3%. Its treatment is under the CPTG, with a 
high level of requests (38%) being initially denied in Minas Gerais because prescribers were 
wrongly completing the forms, leading to potential harm to patients.  
METHODS 
To review international experiences and scientific publications relating to academic detailing 
among countries actively conducting such programmes, including Australia, USA and Canada. 
This was based on a thorough review of available literature including publications known to the 
co-authors, some of whom have considerable experience with developing and conducting 
                                                             
bInstitute for Health Metrics and Evaluation. Global Burden of 
Disease.http://vizhub.healthdata.org/gbd-compare/ 
6 
 
academic detailing programmes. Following completion, use the findings to develop a structured 
DSSURDFKWRDFDGHPLFGHWDLOLQJEDVHGRQWKH&37*IRU$O]KHLPHU¶V'LVHDVHLQ%UD]LO 
Subsequently implement the pilot programme and monitor physician acceptance of academic 
detailing and its impact on future prescribing. To help with this, develop and conduct a 
satisfaction survey by telephone. The survey included questions about the acceptability, 
relevance and the quality of the academic detailing received. The results to be evaluated in 
terms of the feasibility, effectiveness and satisfaction with academic detailing. The feasibility will 
consider the costs incurred with undertaking the planning and conducting the field visits. The 
effectiveness of the academic detailing programme will be determined by analysing the rate of 
returned requests prior to (3 months earlier) and after (3 months later) the programme among 
the control and intervention groups, matched to reduce bias. Finally, the satisfaction survey will 
be analyzed qualitatively and quantitatively to assess the satisfaction and perceptions of the 
physicians and facilitators. The combined results will be used to determine whether academic 
detailing is a worthwhile option to reduce the rate of denied applications to CEAF medicines in 
Brazil.  
RESULTS 
x Literature review 
The systematic review of the effects of guideline implementation strategies identified 22 relevant 
studies involving educational outreach as part of multifaceted interventions compared to no-
intervention (20). The most common combination was educational outreach plus materials 
(34%), followed by educational outreach plus materials and meetings (17%). The authors of the 
published papers concluded that multiple educational outreach visits improved clinical 
performance compared to no intervention by an average of 6-7%, but considered these results 
modest. The results from ten studies (11 comparisons) showed that educational outreach was 
more effective than educational materials as well as audit and feedback with an overall modest 
impact (20).  
Recently systematic reviews of guideline dissemination have been published, with a variety of 
results and control groups. A systematic review aiming to increase influenza vaccination rates 
among those of 60 years or above in the community included one trial with 27,580 participants. 
The authors found that written feedback was more effective than educational outreach plus 
feedback (OR: 0.77, 95%CI: 0.72; 0.81). This same review also included another trial (1,400 
participants) that did not find any difference between educational reminders, academic detailing 
and peer comparisons to other physicians compared to mailed educational materials [OR: 1.13 
(0.80; 1.58)] (28). Another systematic review, evaluating strategies targeting Specialist Mental 
Health Care services, included five studies with only one evaluating academic detailing.This 
review concluded that academic detailing was not effective in reducing antipsychotic co-
prescribing in schizophrenia outpatients (29).  
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On the other hand, Kahn and colleagues (30) analyzed 54 studies and observed that education, 
alerts and multifaceted interventions were associated with statistically significant increases in 
the prescribing of appropriate thromboprophylaxis in hospitalized medical and surgical patients. 
In addition, multifaceted interventions were associated with statistically significant increases in 
the prescription of any prophylaxis.  
In Brazil, Silva and colleagues(31) conducted a randomized controlled clinical trial to evaluate 
the usefulness of academic detailing with increasing pre-natal Group B Streptococcus screening 
in a hospital, in accordance to a Clinical Guideline. They found that the physicians who received 
academic detailing had a higher proportion of women screened compared to physicians 
receiving direct mailing or physicians who did not receive any intervention. 
 
x International experiences with academic detailing  
There are reports of academic detailing initiatives worldwide. However, only a few countries 
have large-scale experiences in developing and maintaining permanent academic Programs. A 
summary of the experiences with academic detailing and the structure of the programs of 
Australia, United States and Canada are shown in Table 2. These findings helped formulate the 
structure of the pilot programme in Brazil (below). 
Academic detailing combined with other interventions, including regular prescribing feedback 
and financial incentives, have also enhanced physician adherence to a limited list of 
pharmaceuticals in Stockholm, Sweden ± WKHµ:LVH/LVW¶ (7, 32).  
Table 2: Selected Experiences with Academic Detailing worldwide 
 NPS MedicineWise National Resource 
Center for 
Academic 
Detailing 
(NaRCAD) 
Canadian Academic 
Detailing Collaboration 
Context Implemented by NPS 
MedicineWise, an 
independent not-for-profit 
organization. Programs 
funded by the Australian 
Government Department of 
Health.  
Spend on medicines:  
Department of Health 
spend on drugs: AU$9.15 
billion on 209.8 million 
prescriptions dispensed in 
year ending 30 June 2014 
(34) 
Through the 
Agency for 
Healthcare 
Research and 
Quality (AHRQ) 
Funded by the U.S 
Government 
Department of 
Health and Human 
Services 
In partnership with the 
Dalhousie Office of 
Continuing Medical 
Education 
Funded by the Nova 
Scotia Department of 
Health  
Spend on medicines:  
Canada spent $23.3 billion 
on 499.6 million 
prescriptions dispensed in 
2010 (35) 
 
Experience 
with AD 
Between January 1999 and 
December 2013, NPS have 
delivered over 140,000 
educational visits to GPs 
and GP registrars. 
At any time between 60-
150 trained professional 
More than 130 
professionals 
trained since 2010 
Conducted 8 
sessions of training 
in the principles and 
techniques of 
The five programs 
together have: 
x Task force of 10.2 Full 
Time Equivalent 
Academic Detailers 
x Each program delivers 
two to five topics per 
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detailers.  
Offer three programs each 
year focused on the quality 
of use of medicines and 
medical tests, with typically 
50% of GPs participating 
Academic Detailing 
and a large number 
of outreach 
presentations 
year 
x Average of 1,000 
doctors reached per 
topic 
 
Therapeutic 
areas 
delivered (in 
successive 
years) 
Asthma; Dyslipidemia; 
Type 2 diabetes 
Hypertension; 
Osteoporosis; Antibiotics; 
Depression; Hormone 
replacement; Menopause; 
NSAID therapies; Heart 
failure; Antipsychotics; 
Dementia; Pain; 
Anticoagulants; Stroke 
COPD 
Diabetes care; HIV 
screening; HIV 
prevention; safer 
use of prescription 
pain medication; 
increased 
vaccination for 
pregnant women; 
improved 
developmental 
screening in 
children; tobacco 
cessation; reduction 
of opioid overdoses; 
safer use of 
medications in 
nursing homes; 
cancer screening 
and many others 
Atrial fibrillation; Statin 
update; Aggressive statin 
therapy; Hormonal 
contraception; 
Dyslipidemia; Pneumonia; 
Fluoroquinolones; Anti-
infective guidelines; 
Parkinson`s treatment; 
Restless legs syndrome; 
Opioids in chronic non-
malignant pain; 
Spironolactone in heart 
failure; Oral vitamin k; 
Transdermal fentanyl; 
Pitfalls in drug therapy; 
Clopidogrel in acute 
coronary syndrome; 
Smoking cessation 
counselling 
Participation 
in the 
programs 
Free and voluntary  
Physicians earn credits for 
Continuing Medical 
Education. 
- 
Free and voluntary  
Physicians earn credits for 
Continuing Medical 
Education. 
Topics 
selection 
Selected after broad 
formative research with: 
Expert advisory groups, 
key informant interviews, 
literature research, drug 
use data, surveys; drug 
adverse events and phone 
line inquiries 
- 
Based on physician 
surveys, practice gaps, 
current topics in the news, 
suggestions from groups 
who identify practice gaps,  
assessment of need, 
available educational and 
financial resources 
 
Training Three-day workshop: 
structure of the 
educational visit; building 
trust and credibility; 
barriers to 
communication; exploring 
values and believes; 
barriers and enablers, 
closure; using 
educational aids; 
handling challenging 
responses; putting all 
together; taking it back to 
workplace. Participants 
are filmed conducting an 
educational visit with a 
GP. 
Two-day workshop: 
theory of Academic 
Detailing, principles of 
social marketing, 
evaluating clinical 
evidence, 
deconstructing an 
Academic Detailing 
call including 
engaging clinicians 
and gaining 
commitment to 
behavioural change, 
small group-practice, 
case-studies, 
evaluation of recorded 
detailing sessions with 
practice clinicians. 
Training includes 
upskilling workshop and 
extensive self-study; 
qualitative and 
quantitative evaluation for 
each topic. 
 
Interventions Multi-faceted 
interventions: Academic 
Detailing, audit and 
feedback, strategic use of 
Multi-faceted 
interventions: 
Academic Detailing 
and printed materials, 
Multi-faceted 
interventions: Academic 
Detailing, guidelines, 
local physician opinion 
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opinion leaders, 
interactive case studies, 
patient mediated 
strategies and 
educational materials  
combined with audit 
and feedback or 
electronic 
interventions, 
depending on the 
context and the 
clinical problem being 
addressed  
leader, printed materials, 
prescribing feedback 
reports  
Visit Mainly conducted by 
pharmacists targeting 
mainly GPs. One-to-one 
visits are expected to 
take up to 30 minutes. 
Facilitated peer group 
discussions up to  1 hour. 
 
One-on-one visits with 
clinicians in their 
practice site 
 
Face-to-face visits or via 
Web conferencing 
sessions in one-on-one 
or small groups;  
Duration of visits range 
from 10 to 30 minutes for 
individuals and 30 to 60 
in group sessions 
 
After visiting Physicians complete an 
evaluation form and the 
educational facilitators 
complete a visit review 
All material for the 
facilitators are available 
through the NPS website 
specific area 
- 
Material of visits, 
questions and answers 
on trials are available 
online. Also publishes 
newsletters in the 
Canadian Family 
Physician journal 
AD: Academic Detailer; GP: General Practitioner 
 
Australia. A pillar of $XVWUDOLD¶V1DWLRQDO0HGLFLQHV3ROLF\LVWKDWWKHUHVKRXOGEHPHFKDQLVPV
to ensure rational and responsible use of medicines. In 1998, NPS MedicineWise, an 
independent, not-for-profit organization, was established to provide a nationally coordinated 
approach to design, develop, implement and evaluate national programs to improve the quality 
use of medicines, and more recently medical tests, in support of this policy (33). 
Each year, NPS MedicineWise delivers at least three national educational programs focused on 
FDUHIXOO\VHOHFWHGWKHUDSHXWLFLVVXHVZLWKPRUHWKDQRI$XVWUDOLD¶VJHQHUDOPHGLFDO
practitioners (primary care physicians) participating. Systematic evaluation has been critical to 
its success and, since inception, the investment in these programs has consistently achieved 
demonstrable improvements in the use of medicines and medical tests. Moreover, the programs 
have resulted in improved health outcomes and savings in government expenditure, far in 
excess of the cost of the programs (34). 
United States. Because the healthcare system in the US is decentralized, there is no 
organization that provides co-ordinated academic detailing services. However, there are many 
individual initiatives of varying sizes and scales. The National Resource Center for Academic 
Detailing (NaRCAD) is an initiative supported by the Agency for Healthcare Research and 
Quality (AHRQ) in the US Department of Health and Human Services. NaRCAD provides 
training, materials, and consultative support to health care organizations who conduct academic 
detailing programs in multiple US States as well as several programs in other countries 
(Personal Communication Michael Fischer). 
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Multiple other public and private organizations run academic detailing programmes in the United 
States, ranging from pediatric screening for developmental problems to the safe use of 
medications in the elderly, e.g. the Alosa Foundation, the Kaiser Permanente system, the 
Veterans Affairs healthcare system. 
 
Canada. The Canadian Academic Detailing Collaboration was founded in 2003 initially with five 
programs. This collaboration works in partnership with the Canadian Agency for Drugs and 
Technologies in Health - CADTH, which develops the information to be disseminated by the 
detailers (35,36).The programmes were developed by a pharmacist alone or in a group 
containing also a specialist physician, urban and rural family physicians.  
x Brazilian Academic Detailing Pilot Programme  
 
Based on the experiences with academic detailing among NPS MedicineWise in Australia, 
NaRCAD in the US, and experiences in Canada, coupled with the findings from the 
comprehensive literature search, an academic detailing pilot programme has been initiated in 
Minas Gerais, Brazil, by the not-for-profit SUS Collaborating Centre for Technology Assessment 
and Health Excellence (CCATES), with an institutional partnership with the Ministry of Health in 
Brazil. It includes nine steps to improve future prescribing (3): 
Step 1: Identifying the subject. A cross-sectional analysis of a random sample of 165 requests 
for Alzheimer`s treatment between Oct 2012 and May 2013 from Minas Gerais state showed a 
38% rate of non-approval. This was mainly due to incongruence or wrong application of the 
cognitive tests (30%) as well as the presence of not eligible conditions including advanced 
disease (12%) or untreated depression (7%). These results suggested non-observance of the 
CPTG inclusion criteria and lack of knowledge in how to perform cognitive tests among 
physicians)RUWKLVUHDVRQ$O]KHLPHU¶VGLVHDVHZDVFKRVHQIRUWKHSLORWVWXG\(37). 
Step 2: Defining the purpose of the Academic Detailing. The purpose of the pilot was to 
disseminate, in Minas Gerais, the &37*IRU$O]KHLPHU¶VGLVHDVHGHYHORSHGE\WKH0LQLVWU\DQG
by the State of Health of Minas Gerais. As a result, improve physician familiarity with the 
guidelines to improve care and reduce future denials. 
Step 3: Providing the team and planning. One expert in the field, two research coordinators, two 
pharmacists and four academics were responsible for planning the academic detailing visits, 
including the outsourced services, educational materials, hiring and training of facilitators. The 
team determined the number of visits required to solve/minimize the identified problem. The 
FDOFXODWLRQRIVDPSOHVL]HZDVEDVHGRQWKHSUHYDOHQFHRIUHWXUQHGUHTXHVWVIRU$O]KHLPHU¶V
Disease treatment found in previous research and subsequently considering a difference of 
20% in the outcome between control and intervention groups, in addition to a 12% possible 
drop-out rate. The estimated sample was 114 participants, 57 for each group. For each 
participant in the intervention group, it was envisaged a minimum of two and a maximum of 
three visits were needed to improve future prescribing according to the CPTG. 
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Step 4: Developing and acquiring support materials. Handouts with key messages to physicians 
and folders for patients and caregivers were developed. These educational materials were 
simple, objective and attractive, with WKHSK\VLFLDQ¶VKDQGRXWFRQVLVWHGRIWKUHHYROXPHV:H
also provided WKH0LQLVWU\RI+HDOWK¶V book of CPTGs, a flash drive containing all the material 
needed to request drugs at the CEAF, and a book documenting how to perform 
multidimensional assessments of the elderly (Figure 1). In each visit, at least one material was 
delivered. 
Figure1 ± Materials provided for the Academic Detailing Programme in Brazil 
 
 
Step 5: Selecting participants. The sample was randomly selected from a database of all 
physicians that requested on at least three occasions PHGLFLQHVIRUWKHWUHDWPHQWRI$O]KHLPHU¶V
disease through the CEAF during the year prior to the study. The prescribers included 
psychiatrists, neurologists, geriatricians and general practitioners. 
Step 6: Recruiting and training facilitators (academic detailers). Eight pharmacists with 
experiences in SUS and in evidence-based medicine concepts were recruited and trained as 
follows: (i) studying the topic in their own time; (ii) learning the principles and techniques of 
academic detailing; (iii) learning the clinical content of the detailing materials; and (iv) simulating 
the visit. In total, the training took an average of 12 hours.  At the end of the training, each 
facilitator received a name card, a badge, the support materials and a list of prescribers to be 
visited. This contained details of their specialty, working address and telephone number. 
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Step 7: Conducting the educational outreach visits. Before the visit, the facilitators checked the 
prescriber address and availability. Once the academic  detailier ZDVDWWKHSUHVFULEHU¶VRIILFH
he/she presented him/herself to the assistant and waited until the prescriber was able to receive 
him/her. Each academic detailer took a notebook with a standardized form to collect data from 
the visit and a space to write any observations.  37 (65%) physicians were visited. The duration 
of the visits depended on the receptivity and availability of the prescriber. All detailers carried 
out at least two visits for each prescriber. It took two months for all academic detailers to visit all 
prescribers. 
Step 8: Conducting a satisfaction survey. All prescribers provided a personal telephone number 
so the team could subsequently conduct a satisfaction survey about the visit. A different team to 
that of the academic detailers was responsible for conducting the telephone survey so 
prescribers could be comfortable in informing their perception regarding the acceptability, 
relevance and the quality of the academic detailing received. The questionnaire used is shown 
in Figure 2. 
Figure 2 ± Questionnaire used to follow-up each visit 
 
Step 9: Evaluating the results. As mentioned, the results are currently being evaluated in terms 
of satisfaction, feasibility and efficacy in line with other studies undertaken to assess the 
influence and impact of academic detailing (38). To date, the satisfaction survey has been 
conducted with 29 physicians. 86.2% reported the maximum level of overall satisfaction with the 
visit. Similar results were obtained for the relevance of the content of the visits (93.1%), 
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resolution of the doubts (72.4%), length of each visit (89.6%), bibliography reliability (96.5%), 
usefulness of the materials to their clinical practice (82.8%), improvement in the understanding 
of the SUS requests of drugs (75.9%) and a better understanding of the inclusion criteria for 
Alzheimer´s treatments to be reimbursed (55.2%). Recognition of the importance to inform the 
education level of patients after the visit was of 82.7%.  
DISCUSSION  
We can find in the literature many strategies aiming to translate the growing body of knowledge 
into regular practice by prescribers, including evidence-based guidelines, continuing medical 
education conferences, academic detailing, opinion leaders giving advice, audit and feedback, 
pay-for-performance, and computer-based reminder systems. These strategies help to close 
gaps in knowledge due to lack of information independent from commercial influence, limited 
efforts by physicians to actively implement evidence-based information, limited 
comprehensibility of the guidelines especially if physicians are expected to know and follow 
multiple guidelines, as well as potentially biased activities from pharmaceutical companies (12, 
13,16, 39,40). 
The development of treatment guidelines, based on explicit assessments of the evidence base, 
has been a strategy of the Ministry of Health to improve the care provided to Brazilian citizens. 
However, there are still challenges regarding their implementation and the extent of their 
compliance.  
Studies have reported reasons why prescribers do not follow guideline recommendations. 
These can be related to the information presented or its usefulness, e.g. doubts about scientific 
grounds for the key recommendations and the applicability of trial data to particular patients, or 
overly complex algorithm for diagnosis/treatment. They can also be related to the prescriber, 
e.g. resistance to a proactive preventive approach and efforts to motivate patients to change 
their lifestyles as well as specific biases and attitudes of general practitioners. Barriers can also 
relate to the preferences of patients or be related to organizational difficulties, e.g. the absence 
of a computerized system, effect of time pressures and financial considerations making the 
subject a low priority, and the absence of an educational mentor (38,41). 
Detecting obstacles to the CPTG implementation is essential in order to develop methods and 
VROXWLRQVDQGFDQEHGRQHWKURXJKD³GLDJQRVWLFDQDO\VLV´RIWKHWDUJHWJURXSEHIRUHLQLWLDWLQJ
the implementation of the guideline (38). Most accepted guidelines DUHWKHRQHV³RZQHGDQG
RSHUDWHG´E\WKHSURIHVVLRQLWVHOILHZKHQWKHWDUJHWJURXSSDUWLFLSDWHVLQWKHFRQVWUXFWLRQ
dissemination and implementation (38). Other strategies include disseminating the guideline in 
pertinent scientific journals or in professional networks (38) and the use of software that 
facilitates diagnosis of a disease and promotes easy access to protocols and criteria, thereby 
increasing the response to the guideline among prescribers (41). Academic detailing, audit and 
feedback activities can be used to identify the need for a review of current guidelines and to 
improve/adapt them to local realities (29).  
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A considerable body of evidence indicates that academic detailing can change healthcare 
practitioner behaviors. However, the overall evidence is heterogeneous in terms of study 
designs, populations studied, target actions and implementation strategies (20). It is reasonable 
to conclude that academic detailing is one of the approaches with better results, especially 
when used as part of a multifaceted intervention. 
As seen, initial feedback is positive and we expect this to continue. However, we need to wait 
until all the findings have been analysed, including all the costs involved coupled with the 
outcomes, before we can make more definitive statements. As soon as these are evaluated, we 
will publish the findings and make all the materials used available online to other researchers, 
prescribers and the public in general. We acknowledge that our study is confined to one locality 
in Brazil. However, we believe the robustness of our approach, including building on 
International experiences, should mean that our results can translate into other disease areas 
and other localities in Brazil.  
The main difference among the ongoing Brazilian academic detailing pilot programme and 
international experiences is that we are targeting specialists, not general practitioners. In 
addition, in Australia and Canada, when a physician participates in educational outreach visits 
they earn credits for their Continuing Medical Education (CME), so although incentivized, they 
participate voluntarily. In Brazil, there is no obligation of CME; consequently, WKHSUHVFULEHU¶V
perception about the need of the visit is restricted to the usefulness of the information and 
materials received to their clinical practice.  However, increased knowledge should result in less 
rejections for authorizing treatments under the CEAF scheme, which should benefit all key 
stakeholder groups. 
CONCLUSION 
The successful experience internationally coupled with our comprehensive approach suggests 
that academic detailing could represent an effective intervention. Consequently, we believe this 
VWUDWHJ\LVZRUWKZKLOHDVDSURSRVDODLPLQJWRLPSURYHSDWLHQWV¶DFFHVVWRDSSURSULDWH
medicines in CEAF through the implementation and dissemination of Clinical Protocols and 
Therapeutic Guidelines in Brazil. We look forward to demonstrating this in practice, building on 
early positive feedback. As a result, we believe we need to further develop academic detailing in 
Brazil to improve the quality of care of patients using trained pharmacists. 
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